Current status of immunisation for herpes zoster
Herpes zoster (HZ) is increasingly common in the aging and is experienced by approximately one in three people in their lifetime. It is also relatively common in immune-compromised people. Acute HZ causes severe pain, reduced quality of life and severe complications, including prolonged pain, or pos...
Saved in:
| Main Authors: | Anthony Lawrence Cunningham, Kerrie Jane Sandgren, Janette Taylor |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2445384 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy, reactogenicity, and safety of the adjuvanted recombinant zoster vaccine for the prevention of herpes zoster in Chinese adults ≥ 50 years: A randomized, placebo-controlled trial
by: Diana Alexandra Echeverria Proano, et al.
Published: (2024-12-01) -
Cost-effectiveness analysis of herpes zoster vaccination for adults aged 50 years in Zhejiang province, China
by: Fuxing Chen, et al.
Published: (2025-05-01) -
The Herpes Zoster Patient Pathway and Gaps in Current Vaccination Guidelines in Southeast Asia: Summary of a Zoster Experts’ Network Scientific Workshop
by: Gyneth Lourdes G. Bibera, et al.
Published: (2024-12-01) -
The Potential Impact of Increased Recombinant Zoster Vaccine Uptake in Older Adults Worldwide
by: Nikolaos Giannelos, et al.
Published: (2025-05-01) -
Effectiveness of recombinant zoster vaccine in reducing herpes zoster incidence and all-cause mortality among patients with rheumatoid arthritis: a retrospective cohort study of 21,046 individuals from TriNetX U.S. Collaborative NetworkResearch in context
by: Ying-Li Lin, et al.
Published: (2025-07-01)